Literature DB >> 19221815

Evaluation of meropenem alone and combined with rifampin in the guinea pig model of pneumococcal meningitis.

E Force1, F Taberner, C Cabellos, S Ribes, A Doménech, F Tubau, P F Viladrich, F Gudiol.   

Abstract

Meropenem is a broad-spectrum carbapenem antibiotic that is highly active against the pathogens causing meningitis. The aims of this study was to determine the efficacies of meropenem alone and combined with rifampin against two Streptococcus pneumoniae strains with different susceptibility to beta-lactams using the guinea pig meningitis model and compare them with the standard ceftriaxone plus vancomycin therapy. All treatments except rifampin were bactericidal from 6 h. The addition of rifampin did not improve the activity of meropenem alone. Our results provide good evidence of the efficacy of meropenem in the treatment of penicillin- and cephalosporin-susceptible and -resistant pneumococcal meningitis similar to that of ceftriaxone plus vancomycin, suggesting that meropenem might be a good option in the management of this infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19221815     DOI: 10.1007/s10096-009-0711-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  21 in total

1.  Emergence of rifampin-resistant Streptococcus pneumoniae as a result of antimicrobial therapy for penicillin-resistant strains.

Authors:  P M van Tilburg; D Bogaert; M Sluijter; A R Jansz; R de Groot; P W Hermans
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

2.  Lack of correlation between in vitro and in vivo studies of combinations of rifampin plus vancomycin or beta-lactam antibiotics against Streptococcus pneumoniae.

Authors:  F Tuban; C Cabellos; J Liñares
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  Evaluation of ceftriaxone, vancomycin and rifampicin alone and combined in an experimental model of meningitis caused by highly cephalosporin-resistant Streptococcus pneumoniae ATCC 51916.

Authors:  Sandra Ribes; Ferran Taberner; Alejandro Domenech; Carmen Cabellos; Fe Tubau; Josefina Liñares; Pedro Fernández Viladrich; Francesc Gudiol
Journal:  J Antimicrob Chemother       Date:  2005-09-20       Impact factor: 5.790

4.  In vitro killing activities of antibiotics at clinically achievable concentrations in cerebrospinal fluid against penicillin-resistant Streptococcus pneumoniae isolated from children with meningitis.

Authors:  C P Doit; S P Bonacorsi; A J Fremaux; G Sissia; R Cohen; P L Geslin; E H Bingen
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

5.  Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges.

Authors:  R Dagan; L Velghe; J L Rodda; K P Klugman
Journal:  J Antimicrob Chemother       Date:  1994-07       Impact factor: 5.790

6.  Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group.

Authors:  C M Odio; J R Puig; J M Feris; W N Khan; W J Rodriguez; G H McCracken; J S Bradley
Journal:  Pediatr Infect Dis J       Date:  1999-07       Impact factor: 2.129

7.  Experimental study of meropenem in the therapy of cephalosporin-susceptible and -resistant pneumococcal meningitis.

Authors:  E Force; F Taberner; C Cabellos; S Ribes; A Domenech; F Tubau; P F Viladrich; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-04-02       Impact factor: 3.267

Review 8.  New therapies for pneumococcal meningitis.

Authors:  P H Cottagnoud; M G Täuber
Journal:  Expert Opin Investig Drugs       Date:  2004-04       Impact factor: 6.206

9.  A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group.

Authors:  E Schmutzhard; K J Williams; G Vukmirovits; V Chmelik; B Pfausler; A Featherstone
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

10.  Efficacy of meropenem in experimental meningitis.

Authors:  K Nairn; G L Shepherd; J R Edwards
Journal:  J Antimicrob Chemother       Date:  1995-07       Impact factor: 5.790

View more
  2 in total

Review 1.  Carbapenems: past, present, and future.

Authors:  Krisztina M Papp-Wallace; Andrea Endimiani; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

Review 2.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.